Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Judd W. Moul, MD, FACS
Advertisement
Articles by Judd W. Moul, MD, FACS
Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
3
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5